Published: 9 June 2020
Author(s): Keren Marks-Garber, Tali Bdolah-Abram, Samir Nusair
Section: Original article

Idiopathic Pulmonary Fibrosis (IPF), a progressively destructive lung disease caused by unchecked fibroblast activity and uncontrolled formation of pulmonary scar tissue,[1] has a median survival from the time of diagnosis, just short of 3 years. The recently approved anti-fibrotic drugs, pirfenidone and nintedanib, are effective in altering disease progression.[2,3] Therefore, increasing clinical awareness and earlier detection of the disease process have become important goals to achieve.[4] Currently, no useful clinical tools exist for the efficient screening and early detection of IPF.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.